Colleen M Salscheider, APRN, CNP in Bemidji, MN - Medicare

Colleen M Salscheider, APRN, CNP is a medicare enrolled "Nurse Practitioner" physician in Bemidji, Minnesota. Her current practice location is 1233 34th St Nw, Bemidji, Minnesota. You can reach out to her office (for appointments etc.) via phone at (218) 333-5522.

Colleen M Salscheider is licensed to practice in Wisconsin (license number 7883) and she also participates in the medicare program. She accepts medicare assignments (which means she accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and her NPI Number is 1245756089.

Contact Information

	Colleen M Salscheider, APRN, CNP
	1233 34th St Nw, Bemidji, MN 56601-5112
	(218) 333-5522
	Not Available

Physician's Profile

Full Name	Colleen M Salscheider
Gender	Female
Speciality
Experience	Years
Location	1233 34th St Nw, Bemidji, Minnesota
Accepts Medicare Assignments	Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Colleen M Salscheider attended and graduated from in

NPI Data:

NPI Number: 1245756089
Provider Enumeration Date: 08/14/2017
Last Update Date: 07/17/2023

Medicare PECOS Information:

PECOS PAC ID:
Enrollment ID:

Medical Identifiers

Medical identifiers for Colleen M Salscheider such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1245756089	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207Q00000X	Family Medicine	7150 (Minnesota)	Secondary
363LA2200X	Nurse Practitioner - Adult Health	788-33 (Wisconsin)	Secondary
363L00000X	Nurse Practitioner	7883 (Wisconsin)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Colleen M Salscheider is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Colleen M Salscheider, APRN, CNP Po Box 5074, Sioux Falls, SD 57117-5074 Ph: () -	Colleen M Salscheider, APRN, CNP 1233 34th St Nw, Bemidji, MN 56601-5112 Ph: (218) 333-5522

News Archive

Matrix metalloproteinase-8 enzyme increases the risk of heart diseases

Scientists at Queen Mary, University of London have made an important discovery in understanding what causes arteries to clog up. They have discovered that an enzyme called matrix metalloproteinase-8 plays a crucial role in raising blood pressure and causing abnormal build-up of cells in the arteries - both of which increase the risk of heart disease.

Opexa completes meetings with FDA regarding planned development program for Tovaxin

Opexa Therapeutics, Inc., a leading cell therapy company developing Tovaxin for multiple sclerosis, today announced the successful completion of two separate meetings with the U.S. Food and Drug Administration regarding the Company's planned development program for Tovaxin.

New treatment guidelines demonstrate that best care does not always cost more

Arizona Oncology is proud to be a part of the larger network that just completed a recently conducted study by US Oncology and Aetna that finds evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes.

European Medicines Agency accepts reviewal of Merck's MAA for regulatory approval of vernakalant IV

Merck & Co., Inc., Whitehouse Station, NJ, USA, which operates in many countries as Merck Sharp & Dohme Limited, announced today that the European Medicines Agency (EMEA) accepted for review the Company's Marketing Authorisation Application (MAA) for regulatory approval of vernakalant intravenous (IV).

Nanotechnology, biomolecules, and light unite to "cook" cancer cells

Using carbon nanotubes linked to tumor-homing antibodies, a research team headed by Ellen Vitetta, Ph.D., M.D., of the University of Texas Southwestern Medical Center has shown that they can specifically kill the targeted tumor cells using near-infrared light. This work appears in the Proceedings of the National Academy of Sciences.

Colleen M Salscheider, APRN, CNP - Medicare in Bemidji, MN